MedTrace Logo

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

NCT05749042 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-03-01

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of concurrent chemoradiotherapy based of cisplatin with sintilimab as first-line therapy for patients with advanced oral cavity squamous cell carcinoma.

Conditions

  • Oral Cavity Squamous Cell Carcinoma

Interventions

DRUG

Sintilimab

Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.

RADIATION

Radiotherapy

Concurrent Chemoradiotherapy Based of Cisplatin

Sponsors & Collaborators

  • Xin-Hua Xu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-18
Primary Completion
2025-01-18
Completion
2025-01-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05749042 on ClinicalTrials.gov